Velesco expands core scientific and quality team

Appoints director of quality and senior pharmaceutical scientist

Contract research organisation Velesco Pharmaceutical Services, which operates from facilities in Plymouth and Kalamazoo, Michigan, US, has added Shirley Smith as director of quality and Yuan Chen as senior pharmaceutical scientist.

Prior to joining Velesco, Smith was quality assurance manager for Richard-Allan Scientific and senior quality assurance manager for Pfizer’s Drug Product and Device Research Group in Kalamazoo, MI.

In conjunction with her role at Velesco, Smith will continue her leadership position at PharmaMed Resources, a quality assurance and regulatory affairs consultancy that services the Medical Device and Pharmaceutical Industries.

Chen has extensive experience in analytical methods development and validation, cleaning verification and validation, and drug release testing.

Before joining Velesco, Chen served in the Pharmaceutical Sciences Division of Pfizer Global R&D as a senior associate scientist for eight years and the Analytical Development Department of Caraco Pharmaceutical Laboratories for two years. Her experience spans the drug development spectrum from early stage development and validation of stability-indicating methods for the release of drug substance and drug product, to later stage projects focused on the detection of residual drugs on manufacturing equipment.

You may also like

Research & Development

Velesco Pharma expands and opens new cGMP-compliant analytical testing laboratory

Increases the breadth of its services to meet client needs
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Subscribe now